1. Journal of Thoracic Oncology
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study 
D. Ross Camidge, MD, PhD, Rafal Dziadziuszko, MD, PhD, Solange Peters, MD, PhD, Tony Mok, MD, Johannes Noe, PhD, Malgorzata Nowicka, PhD, Shirish M. Gadgeel, MD, Parneet Cheema, MD, Nick Pavlakis, MD, PhD, Filippo de Marinis, MD, PhD, Byoung Chul Cho, MD, PhD, Li Zhang, MD, Denis Moro-Sibilot, MD, Ting Liu, MD, PhD, Walter Bordogna, PhD, Bogdana Balas, MD, Barbara Müller, MSc, Alice T. Shaw, MD, PhD 
Journal of Thoracic Oncology 
DOI: /j.jtho
Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

2. Figure 1
Efficacy outcomes (intent-to-treat population): progression-free survival (PFS) (A) and PFS subgroup analysis (B). Medians of PFS are Kaplan-Meier estimates. Hazard ratios were estimated by Cox regression. CI, confidence interval; CNS, central nervous system; ECOG, Eastern Cooperative Oncology Group; IRC, independent review committee; NE, not estimable.
Journal of Thoracic Oncology DOI: ( /j.jtho )
Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

3. Figure 2
Investigator-assessed best overall response (intent-to-treat population): patients treated with alectinib (A) and patients treated with crizotinib (B). CR, complete response; NE, not estimable; PD, progressive disease; PR, partial response.
Journal of Thoracic Oncology DOI: ( /j.jtho )
Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

4. Figure 3
Progression-free survival (PFS) (investigator [INV]) by echinoderm microtubule-associated protein-like 4 gene (EML4)-anaplastic lymphoma kinase gene (ALK) fusion variant in both the tissue and plasma biomarker-evaluable population subgroups.
Journal of Thoracic Oncology DOI: ( /j.jtho )
Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

5. Figure 4
Objective response rate (ORR) (investigator [INV]-confirmed) by echinoderm microtubule-associated protein-like 4 gene (EML4)–anaplastic lymphoma kinase gene (ALK) fusion variant in both the tissue and plasma biomarker-evaluable population subgroups. *Pearson's chi-square test comparing all three variants. CR, complete response; PD, progressive disease; PR, partial response; V, variant.
Journal of Thoracic Oncology DOI: ( /j.jtho )
Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions